Last reviewed · How we verify
Omega-3 fatty acid administration
At a glance
| Generic name | Omega-3 fatty acid administration |
|---|---|
| Sponsor | Brown, Todd, M.D., Ph.D. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (PHASE2)
- NMDA Enhancement Combined With Omega-3 for Early Dementia (PHASE2)
- A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth (PHASE4)
- Pharmacokinetic Study of Eicosapentaenoic Acid (EPA) and Calcium L-5-Methyltetrahydrofolate (L-5-MTHF) After Administration of CreNeuroS® CNS Fish Oil Plus Softgels in Healthy Subjects Under Fasting Conditions (NA)
- OMEGA - Dietary Intervention - COPD Trial (NA)
- Preoperative Fish Oil PN and Prognosis After Constipation Surgery
- NUTRIBRAIN: Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice (POWER) (NA)
- Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omega-3 fatty acid administration CI brief — competitive landscape report
- Omega-3 fatty acid administration updates RSS · CI watch RSS
- Brown, Todd, M.D., Ph.D. portfolio CI